Hemodynamic Effects of Intermittent Pneumatic Compression for Sports

Not Applicable

Completed

• Conditions: Sports Physical Therapy
• Interventions: Device: Intermittent pneumatic compression (AirRelax)

• Registration Number: NCT06168565
• Lead Sponsor: University of Maia

Brief Summary

The aim of this randomized crossover trial is to assess the hemodynamic effects caused by the use of 2 distinct intermittent pneumatic compression protocols on athletes.

The main questions it aims to answer are:

* Does intermittent pneumatic compression enhance athletes blood flow?

* If yes, what pressure is better to cause this enhancement?

Detailed Description

Not available

Study Timeline

• Study Start: 2023-08-25
• Primary Completion: 2023-09-25
• Study Completion: 2023-09-27
• Study First Submitted: 2023-11-24
• Status Verified: 2023-12
• Study First Submitted QC: 2023-12-04
• Study First Posted: 2023-12-13
• Last Update Submitted: 2023-12-19
• Last Update Posted: 2023-12-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 23

Inclusion Criteria

• male gender
• healthy
• competing in soccer of track and field for at least two years
• not have performed any physical activity on the data collection day

Exclusion Criteria

• more than one risk factor for thromboembolism (e.g., use of tobacco, varicose veins)
• injured athletes

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Sequence 2	Intermittent pneumatic compression (AirRelax)	Measures of end-diastolic peak velocity, systolic peak velocity, heart rate, and arterial diameter will be collected for two minutes, two minutes before, at the 8th minute after the start of the IPC administration, and two minutes after the conclusion of each IPC protocol. End-diastolic peak velocity and systolic peak velocity will be measured across different phases of the IPC cycle (all cuffs inflated, half of the cuffs inflated, and all cuffs deflated). Both the athletes and assessors will be unaware of which protocol is being carried out. All protocols will be performed with participants lying down in a supine position, on a stretcher. The moderate pressure protocol applies a pressure of 80mmHg and the high pressure protocol applies a pressure of 200mmHg.
Sequence 1	Intermittent pneumatic compression (AirRelax)	Measures of end-diastolic peak velocity, systolic peak velocity, heart rate, and arterial diameter will be collected for two minutes, two minutes before, at the 8th minute after the start of the IPC administration, and two minutes after the conclusion of each IPC protocol. End-diastolic peak velocity and systolic peak velocity will be measured across different phases of the IPC cycle (all cuffs inflated, half of the cuffs inflated, and all cuffs deflated). Both the athletes and assessors will be unaware of which protocol is being carried out. All protocols will be performed with participants lying down in a supine position, on a stretcher. The moderate pressure protocol applies a pressure of 80mmHg and the high pressure protocol applies a pressure of 200mmHg.

Primary Outcome Measures

Name	Time	Method
End-diastolic peak velocity	2 minutes before the IPC protocol, during (8th minute mark - at different phases of the IPC cycle), and 2 minutes after the conclusion of the 15 minute protocol.	End-diastolic peak velocity will be assessed in a supine position on the right common femoral artery using an ultrasound (Logiq e BT12; General Electric, Fairfield, CT, USA) with a 3 to 12 MHz multi-frequency linear phase array transducer.
Systolic peak velocity	2 minutes before the IPC protocol, during (8th minute mark - at different phases of the IPC cycle), and 2 minutes after the conclusion of the 15 minute protocol.	Systolic peak velocity will be assessed in a supine position on the right common femoral artery using an ultrasound (Logiq e BT12; General Electric, Fairfield, CT, USA) with a 3 to 12 MHz multi-frequency linear phase array transducer.
Arterial Diameter	2 minutes before the IPC protocol, during (8th minute mark), and 2 minutes after the conclusion of the 15 minute protocol.	Assessment of arterial diameter via automatic edge detection software (FMD Studio, Pisa, Italy) measuring the distance between the near and far wall of the intima

Secondary Outcome Measures

Name	Time	Method
Heart rate	2 minutes before the IPC protocol, during (8th minute mark - at different phases of the IPC cycle), and 2 minutes after the conclusion of the 15 minute protocol.	Assess any changes in heart rate.

Trial Locations

Locations (1)

University of Maia; 🇵🇹 Maia, Portugal